Asset Details
Do you wish to reserve the book?
Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study
Do you wish to request the book?
Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phase II study of Didemnin B in central nervous system tumors: A Southwest Oncology Group study
1998
Overview
Didemnin B 6.3 mg/m2 was administered intravenously to 48 patients with recurrent or progressive central nervous system tumors. One patient of 39 (2.9%, 95% confidence limits 0.1 to 13.5) eligible patients had a confirmed partial response utilizing standard solid tumor criteria which lasted 14 months. Toxicity was significant. Nausea and vomiting and lethargy were the most frequent toxicities, but multiple severe toxicities were seen. Further investigation of Didemnin B at this dose is not warranted in patients with central nervous system malignancies.
Publisher
Kluwer,Springer Nature B.V
Subject
/ Adult
/ Aged
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Central Nervous System Neoplasms - drug therapy
/ Female
/ Glioma
/ Humans
/ Male
/ Nausea
/ Oncology
/ Patients
/ Peptides, Cyclic - adverse effects
/ Peptides, Cyclic - therapeutic use
/ Pharmacology. Drug treatments
/ Toxicity
/ Tumors
/ Vomiting
